1. Home
  2. APLM vs SWAG Comparison

APLM vs SWAG Comparison

Compare APLM & SWAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • SWAG
  • Stock Information
  • Founded
  • APLM 2016
  • SWAG 1994
  • Country
  • APLM United States
  • SWAG United States
  • Employees
  • APLM N/A
  • SWAG N/A
  • Industry
  • APLM Blank Checks
  • SWAG Advertising
  • Sector
  • APLM Finance
  • SWAG Consumer Discretionary
  • Exchange
  • APLM Nasdaq
  • SWAG Nasdaq
  • Market Cap
  • APLM 12.3M
  • SWAG 14.7M
  • IPO Year
  • APLM N/A
  • SWAG 2021
  • Fundamental
  • Price
  • APLM $7.02
  • SWAG $1.15
  • Analyst Decision
  • APLM Strong Buy
  • SWAG
  • Analyst Count
  • APLM 2
  • SWAG 0
  • Target Price
  • APLM $425.00
  • SWAG N/A
  • AVG Volume (30 Days)
  • APLM 7.4K
  • SWAG 21.9K
  • Earning Date
  • APLM 03-04-2025
  • SWAG 03-27-2025
  • Dividend Yield
  • APLM N/A
  • SWAG N/A
  • EPS Growth
  • APLM N/A
  • SWAG N/A
  • EPS
  • APLM N/A
  • SWAG N/A
  • Revenue
  • APLM $2,101,000.00
  • SWAG $78,134,000.00
  • Revenue This Year
  • APLM N/A
  • SWAG $11.39
  • Revenue Next Year
  • APLM N/A
  • SWAG N/A
  • P/E Ratio
  • APLM N/A
  • SWAG N/A
  • Revenue Growth
  • APLM 70.54
  • SWAG 21.71
  • 52 Week Low
  • APLM $6.38
  • SWAG $0.73
  • 52 Week High
  • APLM $80.50
  • SWAG $1.63
  • Technical
  • Relative Strength Index (RSI)
  • APLM 37.88
  • SWAG 57.81
  • Support Level
  • APLM $6.70
  • SWAG $1.02
  • Resistance Level
  • APLM $7.60
  • SWAG $1.26
  • Average True Range (ATR)
  • APLM 0.70
  • SWAG 0.11
  • MACD
  • APLM -0.03
  • SWAG 0.00
  • Stochastic Oscillator
  • APLM 22.30
  • SWAG 61.00

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About SWAG Stran & Company Inc.

Stran & Co Inc is an outsourced marketing solutions provider, working closely with customers to develop sophisticated marketing programs that leverage promotional products and loyalty incentive expertise. In addition to selling branded products, It offer its clients with custom sourcing capabilities which is a flexible and customizable e-commerce solution for promoting branded merchandise and other promotional products, managing promotional loyalty and incentives, print collateral, and event assets, order and inventory management, and designing and hosting online retail popup shops. The company purchases products and branding through various third-party manufacturers and decorators and resells the finished goods to customers.

Share on Social Networks: